Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy

We evaluated the efficacy and safety of romiplostim, a thrombopoietin mimetic, in patients with low- or intermediate-risk myelodysplastic syndromes (MDS) receiving azacitidine therapy. Forty patients with low- or intermediate-risk MDS were stratified by baseline platelet counts (< 50 vs ≥ 50 × 10...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kantarjian, Hagop M., Giles, Francis J., Greenberg, Peter L., Paquette, Ron L., Wang, Eunice S., Gabrilove, Janice L., Garcia-Manero, Guillermo, Hu, Kuolung, Franklin, Janet L., Berger, Dietmar P.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2010
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3324162/
https://ncbi.nlm.nih.gov/pubmed/20631375
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-03-274753
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados